Back to top
more

ImmunoGen, Inc. (IMGN)

(Delayed Data from NSDQ)

$2.27 USD

2.27
2,081,350

-0.01 (-0.44%)

Updated Jul 17, 2019 03:58 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.80%
17.93%
9.58%
5.18%
2.03%
10.63%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | A Growth | B Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Will ImmunoGen Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor ImmunoGen.

IMGN

Zacks Equity Research

Why Is ImmunoGen (IMGN) Down 26% Since Last Earnings Report?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN

Zacks Equity Research

Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

BIIB VRTX CELG ADVM IMGN

Zacks Equity Research

ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

FDA advises ImmunoGen (IMGN) to conduct a phase III study to evaluate the safety and efficacy of lead candidate - mirvetuximab soravtansine.

MRK RHHBY IMGN BSTC

Zacks Equity Research

ImmunoGen (IMGN) Misses on Earnings & Revenues in Q1

ImmunoGen (IMGN) reports wider-than-expected loss in Q1 and misses revenue estimates.

MRK RHHBY EDIT IMGN

Zacks Equity Research

ImmunoGen (IMGN) Reports Q1 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 3.23% and -14.13%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

IMGN

Zacks Equity Research

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN

Zacks Equity Research

Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

IMGN

Zacks Equity Research

ImmunoGen (IMGN) Down 50.2% Since Last Earnings Report: Can It Rebound?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN

Zacks Equity Research

Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

Key highlights of the past week are merger agreements plus regulatory and pipeline developments.

CELG BIIB REGN IMGN NITE

Zacks Equity Research

Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.

RHHBY MRK CELG IMGN

Zacks Equity Research

ImmunoGen (IMGN) Beats on Earnings & Sales in Q4, Shares Up

ImmunoGen (IMGN) reports narrower-than-expected loss in Q4 and beats revenue estimates.

RHHBY SNY MRK IMGN

Zacks Equity Research

Options Traders Expect Huge Moves in ImmunoGen (IMGN) Stock

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

IMGN

Zacks Equity Research

ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 15.15% and 14.97%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

IMGN

Zacks Equity Research

Earnings Preview: ImmunoGen (IMGN) Q4 Earnings Expected to Decline

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN

Zacks Equity Research

Roche's Kadcyla Halves Death Risk in Breast Cancer Study

Roche (RHHBY) announces detailed data from a late-stage study on Kadcyla in early breast cancer patients. Kadcyla reduces risk of disease recurrence by 50% compared to Herceptin.

RHHBY NVS IMGN TEVA

Zacks Equity Research

ImmunoGen (IMGN) Down 7.2% Since Last Earnings Report: Can It Rebound?

ImmunoGen (IMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

IMGN

Zacks Equity Research

Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

IMGN

Zacks Equity Research

ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance

ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.

MRK RHHBY IMGN CRSP

Zacks Equity Research

ImmunoGen (IMGN) Reports Q3 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of 8.82% and -8.32%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

IMGN

Zacks Equity Research

ImmunoGen (IMGN) Q3 Earnings Preview: What to Look Out For

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IMGN

Zacks Equity Research

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal.

RHHBY NVS AMGN IMGN

Zacks Equity Research

Are Options Traders Betting on a Big Move in ImmunoGen (IMGN) Stock?

Investors need to pay close attention to ImmunoGen (IMGN) stock based on the movements in the options market lately.

IMGN

Zacks Equity Research

ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.

SNY NVS MRK IMGN

Zacks Equity Research

ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of -3.45% and -34.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

IMGN